Experts: Professor Andreas Hochhaus Director of the Department of Hematology and Medical Oncology Jena University Hospital (Germany) Professor Tiong S Ong Duke-NUS Medical School (Singapore) & Duke University Medical Center, NC (USA)

Program:
Overview of selected oral presentations during the meeting:

Clinical highlights:

• Balancing tolerability and efficacy goals of patients and physicians through shared treatment decision-making
• Selectivity of kinase inhibitors
• ASCEMBL study results
• Asciminib resistance mutations (from published studies)
• Combination therapy of asciminib and ponatinib was effective in the treatment of blast phase CML CDX model
• Rough guide to 3L+ therapies
• TIGER study results
• FASCINATION German CML XI study results
• Prognostic factors for 3-year MMR maintenance in CML patients in the EURO-SKI trial

Biological highlights:

• Current areas of translational research interest in chronic myeloid leukemia
• Combination of large spleen size and low in vivo kinase inhibition in an early predictor of inferior molecular response for patients with CML
• What can we learn from single cell studies in chronic myeloid leukemia?
• Drug profiling for CML blast crisis
• Identification of novel factors controlling non genetic cell plasticity in chronic myeloid leukemia
• Mechanisms of trombogenesis in patients with chronic myeloid leukemia under treatment with ponatinib and other TKIs
• Timing and clonal trajectory to chronic myeloid leukemia driven by the Philadelphia chromosome

Q&A Session

If you have any questions or comments to the speakers, please email info@cml-foundation.org.